Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […] The post 2024 Dealmaking: What’s the Score? appeared first on Evaluate.| Evaluate
How do in-licensing teams in pharma companies discover hidden gems – or even the next blockbuster in their dealmaking?| Evaluate
If you missed our dealmaking trends webinar, here are 3 things we learned about unpartnered assets, M&A and partnerships.| Evaluate
Missed our World Preview webinar? Check it out on-demand to get the highlights from our panel as they discuss the latest pharma forecasts.| Evaluate
Over the last 10 years, large pharma companies have spent an average of $120bn across pharma R&D and business development investments.| Evaluate
Our World Preview report features pharma forecasts out to 2030. The theme this year is “Pharma’s Growth Boost”.| Evaluate